Charles River Laboratories to Present at Upcoming Investor Conferences

Charles River Laboratories International, Inc. (NYSE: CRL) will present at three virtual investor conferences.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/09/2020 - 08:30 AM EST

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will virtually present at three upcoming investor conferences, including:

Credit Suisse 29^th Annual Virtual Healthcare Conference on Tuesday, November 10^th, at 10:15 a.m. EST;
Jefferies Virtual London Healthcare Conference on Wednesday, November 18^th, at 2:40 p.m. GMT (9:40 a.m. EST); and
Evercore ISI 3^rd Annual HealthCONx Conference on Wednesday, December 2^nd, at 9:40 a.m. EST.

Management will present an overview of Charles River’s strategic focus and business developments.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each event and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.